Trial reportClinical and translational science2021
REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics.
Trial report in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics.Clinical and translational science · 2021Trial
- Article
- Nanobody-based IgG simultaneously inhibit the allergenic and enzymatic activity of the dominant honeybee venom allergen.Nature communications · 2026Article
- Innovative Strategies to Reduce Exposure and Expression of the Major Cat Allergen Fel d 1.Clinical and translational allergy · 2025Review
- Furry Animal Allergy: Lipocalins, Serum Albumins, and Secretoglobins-Cross-Reactivity, Diagnosis, and Management Strategies.Clinical reviews in allergy & immunology · 2025Review
- Epitope-Specific Antibodies in Allergic Disease and Clinical Tolerance.Immunological reviews · 2025Review
- Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.Journal of clinical medicine · 2025Review
- Single-Domain Antibodies-Novel Tools to Study and Treat Allergies.International journal of molecular sciences · 2024Review
- Trimeric Bet v 1-specific nanobodies cause strong suppression of IgE binding.Frontiers in immunology · 2024Article
- The holo beta-lactoglobulin lozenge reduces symptoms in cat allergy-Evaluation in an allergen exposure chamber and by titrated nasal allergen challenge.Clinical and translational allergy · 2023Article
- Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Journal of clinical medicine · 2023Review
- IgG in the control of FcεRI activation: a battle on multiple fronts.Frontiers in immunology · 2023Review
- Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma.Biomedicines · 2022Review
- Biologics as novel therapeutics for the treatment of allergy: Challenges and opportunities.Frontiers in allergy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
REGN1908-1909, a 1:1 cocktail of two fully human IgG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.